| Event-free survival by residual cancer burden after neoadjuvant pembrolizumab+ chemotherapy versus placebo+ chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. L Pusztai, C Denkert, J O'Shaughnessy, J Cortes, RA Dent, HL McArthur, ... Journal of Clinical Oncology 40 (16_suppl), 503-503, 2022 | 47 | 2022 |
| Application of a novel mass spectrometric (MS) method to examine exposure to Bisphenol-A and common substitutes in a maternal fetal cohort ES Ihde, S Zamudio, JM Loh, Y Zhu, J Woytanowski, L Rosen, M Liu, ... Human and Ecological Risk Assessment: An International Journal 24 (2), 331-346, 2018 | 25 | 2018 |
| Family-wise error rate controlling procedures for discrete data Y Zhu, W Guo Statistics in Biopharmaceutical Research 12 (1), 117-128, 2020 | 7 | 2020 |
| Abstract PD3-01: Neoadjuvant pembrolizumab+ chemotherapy vs placebo+ chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant … H McArthur, J Cortés, R Dent, J O’Shaughnessy, L Pusztai, S Küemmel, ... Cancer Research 83 (5_Supplement), PD3-01-PD3-01, 2023 | 5 | 2023 |
| Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 L Pusztai, C Denkert, J O’Shaughnessy, J Cortes, R Dent, H McArthur, ... Annals of Oncology, 2024 | 2 | 2024 |
| Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab+ chemotherapy vs placebo+ chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC … P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... Cancer Research 82 (4_Supplement), GS1-01-GS1-01, 2022 | 2 | 2022 |
| MHTdiscrete: Multiple Hypotheses Testing for Discrete Data Y Zhu, W Guo R package version: 1.0.1, 2018 | 2 | 2018 |
| LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC … YH Park, SA Im, JH Ahn, MH Kim, J Cortés, RA Dent, L Pusztai, ... Annals of Oncology 34, S1467-S1468, 2023 | | 2023 |
| Abstract CT067: Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS≥ 50%: phase 3 … M Moskovitz, I Okamoto, P Chen, J Patel, S Mekan, MC Pietanza, Y Zhu, ... Cancer Research 83 (8_Supplement), CT067-CT067, 2023 | | 2023 |
| Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 … S Kummel, P Schmid, N Harbeck, M Takahashi, M Untch, JF Boileau, ... BREAST 68, S63-S64, 2023 | | 2023 |
| Package ‘MHTdiscrete’ Y Zhu, W Guo, MY Zhu | | 2022 |
| gMCPLite: Lightweight Graph Based Multiple Comparison Procedures Y Zhu, Y Zhang, X Deng, K Anderson, N Xiao, KRMCP package), ... R package version: 0.1.2, 2022 | | 2022 |
| Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival … P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kummel, J Bergh, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 18, 117-118, 2022 | | 2022 |
| KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer H McArthur, J Cortes, R Dent, L Pusztai, S Kummel, J Bergh, C Denkert, ... ANNALS OF SURGICAL ONCOLOGY 29 (SUPPL 2), 338-338, 2022 | | 2022 |
| A Process to Validate Internal Developed R Package under Regulatory Environment M Ginnaram, S Ye, Y Zhu, Y Zhang PharmaSUG 2021, 2021 | | 2021 |
| A Strategy to Develop Specification for R Functions in Regulated Clinical Trial Environments A Yang, Y Zhu, Y Zhang PharmaSUG 2021, 2021 | | 2021 |
| PPQplan: Process Performance Qualification (PPQ) Plans in Chemistry, Manufacturing and Controls (CMC) Statistical Analysis Y Zhu, MC Inc. R package version: 1.1.0, 2020 | | 2020 |
| R Package Oriented Software Development Life Cycle in Regulated Clinical Trial Environments Y Zhu, R Jajoo, C Bai, S Nepal, D Woodie, K Anderson, Y Zhang PhUSE US Connect 2020, 2020 | | 2020 |
| PPQplan: Process Performance Qualification (PPQ) Plans in Chemistry, Manufacturing and Controls (CMC) Statistical Analysis Y Zhu 10.5281/zenodo.3405374, 2019 | | 2019 |
| Topics on multiple hypotheses testing and generalized linear model Y Zhu http://archives.njit.edu/vol01/etd/2010s/2017/njit-etd2017-131/njit-etd2017 …, 2017 | | 2017 |
Lajos PusztaiYale School of MedicineEmail verificata su yale.edu
